Time filter

Source Type

Daneshmand A.R.,Blood Transfusion Research Center | Forouzandeh H.,Ahvaz Jundishapur University of Medical Sciences | Azadi M.,Shiraz University of Medical Sciences | Cheraghzadeh Dezfuli S.,Esfahan University of Medical science
Iranian Journal of Blood and Cancer | Year: 2015

Background: This study made an attempt to make the quantitative and qualitative evaluation of hematological research output in five Islamic countries; Iran, Turkey, Malaysia, Saudi Arabia and Egypt; which have the most scientific productions from 1996-2013. Materials and Methods: The current study was carried out during the 1st to 31st of September, 2014 in Blood Transfusion Research Center, Shiraz, Iran. This bibliometric study evaluated quantities and qualities of publications on hematological researches based on SCImago Journal Ranking, for over 17 years (1996- 2013). Strategy of the research was based on the keyword “hematology “. Neither language nor document type restrictions were considered. Data were extracted, tabulated, and compared to identify the ranks as well as trends. The ranking and analyzing indicators included were: ‘number of documents’, ‘citable documents’, ‘citation’, ‘self-citation’, ‘cites per documents’, ‘H-index’, ‘sited documents’, and ‘international collaboration’ . Results: The 5 Islamic countries published a total of 6914 documents in the field of hematology in this period. This number represents 0.248 % of the total documents produced globally in the field of hematology. Results revealed an increase in the number of publications and citable documents for these countries during 1996-2013. Comparison among these countries showed that Turkey, Iran, Egypt have the highest number of documents and citable documents, respectively. Furthermore Turkey and Iran led qualitative indicators like H-index and citation. Conclusion: Despite considerable improvement in recent years these Islamic countries should further support their scientific institutes to increase the quantity and quality of hematology publications. © 2014, Iranian Pediatric Hematology and Oncology Society. All rights reserved. Source

Behnava B.,Baqiyatallah Research Center for Gastroenterology and Liver Diseases | Keshvari M.,Blood Transfusion Research Center | Miri S.M.,Baqiyatallah Research Center for Gastroenterology and Liver Diseases | Elizee P.K.,Baqiyatallah Research Center for Gastroenterology and Liver Diseases | Alavian S.-M.,Baqiyatallah Research Center for Gastroenterology and Liver Diseases
Experimental and Clinical Hepatology | Year: 2011

Interferon, as an immunomodulatory agent, may be responsible for reactivation of Brucellosis in immunocompromised patients such as subjects with thalassemia. We report a case of 52 year old man with brucellosis reactivation during the therapy with Pegylated Interferon-alpha for chronic HCV infection. History included: previous living in rural area, tangent with sheep and cattle, prolonged fever and night sweats. At 16 weeks of treatment patient was negative for HCV-RNA PCR but experienced flu-like syndrome. Afterwards, weight loss and positive serologic studies for brucellosis were present. Antibiotic therapy leaded to a good clinical response within a few days and for the six months later. In endemic region, the past history of brucellosis should be considered prior to start of Interferon-alpha therapy particularly in the immunocompromised hosts. © E&C Hepatology, 2011. Source

Ziaei-Hezarjaribi H.,Mazandaran University of Medical Sciences | Ghaffarifar F.,Tarbiat Modares University | Dalimi-Asl A.,Tarbiat Modares University | Sharifi Z.,Blood Transfusion Research Center | Niaz-Jorjani O.,Golestan University of Medical Sciences
Journal of Mazandaran University of Medical Sciences | Year: 2014

Background and purpose: Previous Research shows the use of plasmids containing genes TSA to be useful as vaccines for Leishmania major. Recently, the role of interleukin-22 (IL-22) in tissue repair has been demonstrated. In this research, the effect of IL-22 on encoding TSA gene of Leishmania major in BALB/c mice was assessed.Materials and methods: pcDNA3 plasmid containing the gene encoding TSA protein (pcTSA) of Leishmania major, along with the cytokine IL-22 was used. 60 BALB/c mice were divided to 4 groups of 15. Control groups received pcDNA3 and PBS and a group was vaccinated intramuscularly with the TSA gene containing plasmid. Fourth group received plasmid containing the gene for the TSA and IL-22 protein. IL-4 and interferon gamma (IFN-γ) levels (MTT test) were used to evaluate the cellular immunity and IgG2a, IgG1 and Total IgG levels [enzyme-linked immunosorbent assay (ELISA) method] to evaluate the humoral immunity. Measuring the diameter of the lesions and the age and weight of the mice was performed.Results: The simultaneous use of plasmid containing the gene encoding protein TSA and IL-22 significantly increased the mean level of IFN-γ and reduced the mean level of IL-4 compared to the other groups. While the mortality rate at 27th week after intervention was 100 % in the control group, the surveillance rates of pcTSA and pcTSA + IL-22 groups were 80%. pcTSA + IL-22 group had the highest weight in 30th week. pcTSA + IL-22 group had significantly smaller lesions compared to control and pcTSA groups.Conclusion: Results show the efficacy of pcTSA + IL-22 in improving the vaccination of cutaneous leishmaniasis. © 2014 Mazandaran University of Medical Sciences. All rights reserved. Source

Ghasemzadeh M.,Monash University | Ghasemzadeh M.,Blood Transfusion Research Center | Hosseini E.,Blood Transfusion Research Center
Thrombosis Research | Year: 2013

Platelet activation is known to be associated with the release of a vast array of chemokines and proinflammatory lipids which induce pleiotropic effects on a wide variety of tissues and cells, including leukocytes. During thrombosis, the recruitment of leukocytes to activated platelets is considered an important step which not only links thrombosis to inflammatory responses but may also enhance procoagulant state. This phenomenon is highly regulated and influenced by precise mutual interactions between the cells at site of vascular injury and thrombi formation. Platelet-leukocyte interaction involves a variety of mediators including adhesion molecules, chemokines and chemoattractant molecules, shed proteins, various proinflammatory lipids and other materials. The current review addresses the detailed mechanisms underlying platelet-leukocyte crosstalk. This includes their adhesive interactions, transcellular metabolisms, induced tissue factor activity and neutrophil extracellular traps formation as well as the impacts of these phenomena in modulation of the proinflammatory and procoagulant functions in a reciprocal manner that enhances the physiological responses. © 2012 Elsevier Ltd. Source

Hosseini E.,Monash University | Hosseini E.,Blood Transfusion Research Center | Schwarer A.P.,Monash University | Jalali A.,Tehran University of Medical Sciences | And 2 more authors.
Leukemia Research | Year: 2013

Since relapse following allogeneic hematopoietic stem cell transplantation (HSCT) can be due to the escape of the residual malignant cells from the graft- versus-leukemia (GvL) effect and given the role of NK cells in GvL and the importance of HLA-E in the modulation of NK cell function, we investigated whether polymorphisms of HLA-E molecule could impact on the incidence of relapse and the improvement of Disease-free Survival (DFS) after allogeneic HSCT. The study group included 56 pairs of donors and patients with malignant hematological disorders undergoing HLA-E matched allogeneic HSCT. The median follow-up was 43.6 (range 20.5-113.1) months. They were genotyped for HLA-E locus using a sequence-specific primer (SSP)-PCR. We found a lower incidence of relapse (p= 0.02) in the patients with HLA-E* 0103/0103 genotype compared to those with other genotypes of HLA-E. We also showed an association between HLA-E* 0103/0103 genotype and a better DFS (p= 0.001). Our results suggest a protective role for HLA-E* 0103/0103 genotype against relapse and an association between this genotype and an improved DFS following HLA-E matched allogeneic HSCT. © 2013 Elsevier Ltd. Source

Discover hidden collaborations